Hypophosphatemia Risk Associated With Intravenous Iron Therapies For Iron Deficiency Anemia

Home / Intelligence / Scientific Publications / Hypophosphatemia Risk Associated With Intravenous Iron Therapies For Iron Deficiency Anemia

The purpose of this study was to systematically assess rates of treatment-emergent hypophosphatemia among IDI formulations used in IDA.

Authors

Lim-Watson M, Libre M, Karkare S, Alkhateeb Z, Hadker N, Bajic-Lucas A, Dahl N, Strauss W, Glaspy J

Journal

ISPOR Meeting, May 2019

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.